News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 181–216
- Matches
- 693
- Sources here
- 25
- Companies here
- 15
Search results
Stored financial headlines
Active search
693 matching headlines
Ticker or company: SUMMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
News | Summit Hotels CEO: Second-quarter success about 'more than the World Cup'
Summit Hotel Properties CEO Jonathan Stanner reported strong second-quarter results, emphasizing that success extended beyond the FIFA World Cup due to a broad lift in business transient and group travel. The company saw meaningful revenue per available room and earnings growth in various urban …
INN
main company
Sharemaestro market context
Trend signal active
52 weeks +17.1%
Summit expands ivonescimab's challenge to Keytruda into bladder cancer
Summit Therapeutics is expanding its ivonescimab development beyond lung cancer by initiating the HARMONi-GU1 Phase II/III trial for bladder cancer. This trial will test ivonescimab plus Astellas/Pfizer's Padcev against Merck's Keytruda plus enfortumab vedotin for first-line treatment of advanced urothelial carcinoma. The company aims …
SMMT
main company
Sharemaestro market context
Price below Trend Line
52 weeks -49.0%
Summit Therapeutics (SMMT) Could Be 52% Undervalued Following New Ivonescimab Trial Updates
Summit Therapeutics (SMMT) is currently assessed as 52% undervalued, with a fair value estimated at $28.36 against its closing price of $13.76. This valuation is largely based on ambitious assumptions regarding its ivonescimab program, which recently expanded with a new global Phase II/III bladder …
Sharemaestro market context Price below Trend Line 52 weeks -31.8% · Next-week setup negative 7.4%Summit Therapeutics Launches HARMONi-GU1 Trial for Ivonescimab in Bladder Cancer
Summit Therapeutics has launched the HARMONi-GU1 trial, a global Phase II/III study evaluating ivonescimab in combination with an antibody-drug conjugate for bladder cancer. Ivonescimab is a bispecific antibody that blocks both PD-1 and VEGF pathways. This trial represents an expansion of Summit's HARMONi program, …
SMMT
main company
Sharemaestro market context
Price below Trend Line
52 weeks -49.0%
Sumitomo Mitsui Financial Group ADR (SMFG-N) Stock Price and News
This article provides stock information for Sumitomo Mitsui Financial Group ADR (SMFG-N), including its current price, historical data, and related news. It details the company's profile as a financial holding company with various functions and subsidiaries. The page also lists market data, analyst ratings, …
SMFG
main company
Sharemaestro market context
Trend signal active
52 weeks +59.5% · Next-week setup positive 60.8%
Consumer Portfolio Services Releases Q2 2026 Financial Results
Consumer Portfolio Services (CPSS) announced its Q2 2026 financial results, reporting a diluted EPS of $0.27, a 35% increase year-over-year, and net income of $6.2 million. The company's revenue climbed 10.6% to $121.4 million, with its total portfolio balance reaching $4.31 billion. Wall Street …
CPSS
main company
Sharemaestro market context
Trend signal active
52 weeks +12.3%
Summit Therapeutics (NASDAQ: SMMT) launches Phase II/III HARMONi-GU1 bladder cancer study
Summit Therapeutics (NASDAQ: SMMT) has initiated the global Phase II/III HARMONi-GU1 study for ivonescimab in urothelial carcinoma (bladder cancer). This randomized trial will evaluate ivonescimab plus enfortumab vedotin against pembrolizumab plus enfortumab vedotin as a first-line treatment for locally advanced or metastatic urothelial carcinoma, …
SMMT
main company
Sharemaestro market context
Price below Trend Line
52 weeks -49.0%
(SSBI) Movement Within Algorithmic Entry Frameworks
The article discusses the algorithmic entry frameworks for Summit State Bank (NASDAQ: SSBI), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The analysis …
SSBI
main company
Sharemaestro market context
Price below Trend Line
52 weeks +13.1%
Consumer Portfolio Services, Inc. - Common Stock (CPSS) Stock Price, News, Quote & History
This page provides comprehensive information on Consumer Portfolio Services, Inc. (CPSS), including its current stock price, financial metrics, and a history of news and press releases. The company specializes in automobile financing for consumers with less-than-perfect credit. Recent news highlights include strong Q2 2026 …
CPSS
main company
Sharemaestro market context
Trend signal active
52 weeks +12.3%
Summit Hotel Properties: Q2 Earnings Snapshot
Summit Hotel Properties (INN) exceeded Wall Street expectations for its second-quarter earnings, reporting funds from operations (FFO) of $34.9 million, or 29 cents per share, surpassing the average analyst estimate of 28 cents per share. The real estate investment trust, specializing in higher-end hotels, …
INN
main company
Sharemaestro market context
Trend signal active
52 weeks +17.1%
UBS Group (INN) discloses 8.08% Summit Hotel Properties stake on Schedule 13G
UBS Group AG and its subsidiaries have disclosed an 8.08% beneficial ownership stake in Summit Hotel Properties, Inc., totaling 8,757,861 shares of common stock, through a Schedule 13G filing. The filing indicates shared voting power over 8,753,313 shares and shared dispositive power over all …
INN
main company
Sharemaestro market context
Trend signal active
52 weeks +17.1%
DBS Remains a Buy on Sumitomo Mitsui Financial Group (SMFNF)
DBS maintained a Buy rating on Sumitomo Mitsui Financial Group (SMFNF) with a price target of Yen7,660.00. Analyst Lim Rui Wen, who covers the Financial sector, has an average return of 22.6% and an 81.58% success rate on recommended stocks. Despite a "Strong Buy" …
SMFG
main company
Sharemaestro market context
Trend signal active
52 weeks +59.5% · Next-week setup positive 60.8%
Legacy Ridge Capital Partners’ Exit from Summit Midstream Corporation (SMC) Marks End of a Costly Mistake
Legacy Ridge Capital Management sold its stake in Summit Midstream Corporation (SMC) in the first half of 2026, admitting it was a "massive investing mistake" dating back to 2017. Despite some improvements under CEO Heath Deneke, the firm felt a more aggressive strategy for …
SMC
main company
Sharemaestro market context
Trend signal active
52 weeks +69.1%
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
HARMONi-GU1 Is First Global Registrational Clinical Trial of Ivonescimab in a Genitourinary (GU) Cancer, Adding to Global Phase III Ivonescimab Studies in NSCLC and CRC Clinical Trial Site Activations Globally Planned to Begin by Q4 2026 MIAMI, August 05, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: …
Sharemaestro market context Price below Trend Line 52 weeks -31.8% · Next-week setup negative 7.4%SUMMIT HOTEL PROPERTIES REPORTS SECOND QUARTER 2026 RESULTS
Summit Hotel Properties (INN) announced strong second-quarter 2026 results, with operating income increasing 27.3% to $28.9 million and Adjusted EBITDAre rising 7.7% to $54.8 million. The company's pro forma RevPAR grew 5.0%, driven by a 7.1% increase in average daily rates, leading to an …
INN
main company
Sharemaestro market context
Trend signal active
52 weeks +17.1%